Diabetes Technology Updates From ATTD 2025: Bi-Hormonal Closed-Loop Systems, Continuous Ketone Monitors & Cell Based Therapy for Type 1 Diabetes
Endocrinologists Dr. Steve Edelman and Dr. Jeremy Pettus share most significant diabetes breakthroughs from the ATTD 2025 Diabetes Congress in Amsterdam
In this video you will learn about:
✔ The debate on using “time in tight range” (70-140 mg/dL) vs. standard time in range (70-180 mg/dL) for CGM metrics
✔ Abbott’s upcoming continuous ketone monitor that measures both glucose and ketones with 14-day wear
✔ Extensive data supporting hybrid closed loop systems across diverse patient populations with improved outcomes
✔ Progress toward fully closed loop systems that don’t require meal announcements
✔ Teplizumab (Tzield) showing promise for newly diagnosed Type 1 patients in the PROTECT study
✔ Vertex’s advancing cellular therapy using stem cell-derived islet cells for patients with severe hypoglycemia
Diabetes technology is advancing at breakneck speed. Drs. Edelman and Pettus, both Type 1 patients themselves, highlight game-changing developments from Amsterdam: Abbott’s upcoming dual glucose-ketone monitor for early DKA detection, hybrid closed loop systems moving toward fully automated insulin delivery without meal announcements, and promising bi-hormonal systems adding glucagon to prevent lows. Meanwhile, Teplizumab shows exciting potential for preserving insulin production in newly diagnosed Type 1s, while Vertex’s stem cell-derived islet therapy nears completion of initial trials, offering hope for those with severe hypoglycemia—all signaling we’re entering a new era in diabetes care.
LEARN MORE ABOUT THIS TOPIC
Highlights from the Recent Diabetes Technology Meetings in Europe (ATTD 2024)
Join us as we talk about our experience at the 18th Annual Diabetes Technology Meeting in Europe (ATTD 2024). In this podcast, we’ll be unpacking our favorite lectures from the event, which hold some very exciting data and insights. From cutting-edge advancements in diabetes technology to the latest developments in medications, we’ll cover it all. Tune in as we explore the forefront of diabetes innovation and share our experiences from this meeting!
FDA Denies SGLT Drug, Dexcom + Oura Ring, Abbott's Ketone Monitor, Medtronic KLUE
Watch Dr. E take on the FDA (spoiler: it didn’t end well) over their controversial SGLT inhibitor denial for Type 1 diabetes. Discover why Dexcom and Oura Ring are the new power couple of diabetes tech, geek out over Abbott’s groundbreaking dual glucose-ketone monitor, and learn how Medtronic’s new Klue smartwatch can tell when you’re sneaking that midnight snack (and bolus for it too!). With their signature mix of cutting-edge information and slightly inappropriate jokes, this episode delivers the diabetes news you need in that signature entertaining TCOYD style.
Leave a Reply